Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative breast cancer (TNBC), but could be heading for use in previously untreated ...
Historically, most companies have focused their time, energy and resources on their bottom lines and securing the best financial performance for their shareholders. But times are changing and people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback